How much does Xarelto cost with Medicare in New Jersey?

Xarelto (rivaroxaban) is a factor Xa inhibitor (a direct oral anticoagulant), the same family as Eliquis. Besides stroke prevention in atrial fibrillation and clot treatment, a low 2.5 mg dose is used with aspirin to cut the risk of major events in coronary or peripheral artery disease. In 2024, 8,458 New Jersey prescribers wrote it for 39,574 Part D members. 2027 is a transition year, so check how your plan handles brand versus generic.

Xarelto under Medicare Part D: 2026 price, generic approvals and New Jersey use

Xarelto	Amount
New Jersey Part D members who filled Xarelto (2024)	39,574
New Jersey gross cost per 30-day fill (2024)	$519.18
New Jersey patient share per 30-day fill (2024)	$48.26
Medicare negotiated price, 30 days (2026 only)	$197
First generic approval, 2.5 mg tablets	March 3, 2025
First generic approvals, atrial fibrillation use	May 14, 2025
Removed from negotiation	January 1, 2027
Most common tier on renewing Part D plans for 2027 (national)	Tier 3 (3,570 of 4,748 plans)

Source: CMS fact sheet: negotiated prices for initial price applicability year 2026.

Generic rivaroxaban: what FDA approved

FDA approved the first generics of Xarelto 2.5 mg tablets, from Lupin and Taro, on March 3, 2025. On May 14, 2025 it added nine more first-generic rivaroxaban tablet approvals for reducing stroke risk in nonvalvular atrial fibrillation, and a generic oral suspension followed in June 2025. FDA reminds readers that an approval does not guarantee a product is on pharmacy shelves, so ask your pharmacist which strengths are actually stocked.

What the 2027 removal means for your plan

CMS determined in October 2025 that Xarelto leaves the negotiation program effective January 1, 2027. CMS takes that step once a generic naming the brand as its reference is approved and marketed. For 2027, the $197 figure no longer applies, and each plan decides whether brand Xarelto, generic rivaroxaban or both are on its drug list, and on which tier.

Spending was already shifting. Nationally, 1,258,760 people with Part D used Xarelto in 2025, at $1,006.21 gross per claim; in the first quarter of 2026 the per-claim figure was $374.04.

Worked example: 2026 versus 2027

In 2026, at $197 with the standard $615 deductible and 25% coinsurance, three full-price fills and a $67.25 fill clear the deductible, then each fill is $49.25. Twelve months total $1,052.25.

For 2027 no Medicare price is published for brand Xarelto, so a yearly figure cannot be worked out honestly. What is fixed: your plan's drug deductible can be no more than $700, and your own out-of-pocket cost for covered drugs stops at $2,400 for the year. If your plan covers generic rivaroxaban on a lower tier, the 25% share or copay applies to a smaller price.

Help with the bill

The XARELTO withMe Savings Card is for commercially insured patients. The Janssen cost page lists Extra Help and the Johnson & Johnson Patient Assistance Program for Medicare members. The program considers Part D members who show they are not eligible for the Low-Income Subsidy and spend more than 4% of gross household income on prescriptions (833-742-0791).

In New Jersey, PAAD covers prescribed legend drugs for people who qualify, at $5 for a generic and $7 for a brand-name prescription, so a switch to generic rivaroxaban would also lower a PAAD copay. PAAD requires a Part D plan alongside it (NJ Division of Aging Services).

If your 2027 plan drops brand Xarelto

Part D plans must give a new member a temporary transition fill when a drug they already take is not on the plan list, which buys time to switch to a covered version or to file a coverage exception with your prescriber. Do not let the bottle run out before you know which rivaroxaban your 2027 plan covers.

Plans are already reshuffling: for 2027, 368 renewing Part D plans nationwide moved rivaroxaban to a higher tier and 340 to a lower one, per CMS formulary files. In New Jersey during 2024, 355,512 thirty-day fills of Xarelto cost $184,575,485 gross; members paid $17,156,764 of that, an average of $433.54 per person over the year.

Short courses after hip or knee surgery

Orthopedic surgeons often send patients home after a hip or knee replacement with a short course of rivaroxaban lasting weeks rather than months. A course that brief usually lands inside your drug deductible, so you may pay the full plan price for it. At the 2026 negotiated $197 per month that is manageable; in 2027, ask before surgery which version the plan covers and what it charges, so the discharge prescription is not a surprise.

Related questions

Sources

1. CMS Medicare Part D Prescribers by Geography and Drug, 2024 (New Jersey) Centers for Medicare & Medicaid Services
2. CMS fact sheet: negotiated prices for initial price applicability year 2026 Centers for Medicare & Medicaid Services
3. CMS: Selected drugs and negotiated prices Centers for Medicare & Medicaid Services
4. CMS Medicare Quarterly Part D Spending by Drug Centers for Medicare & Medicaid Services
5. Medicare.gov: How much does Medicare drug coverage cost? Centers for Medicare & Medicaid Services
6. FDA Roundup: March 4, 2025 U.S. Food and Drug Administration
7. FDA: 2025 First Generic Drug Approvals U.S. Food and Drug Administration
8. Janssen: Xarelto cost and support Janssen Pharmaceuticals
9. CMS Monthly Prescription Drug Plan Formulary and Pharmacy Network Information (CY2026 and CY2027 basic drugs formulary), with the CMS 2027 plan crosswalk Centers for Medicare & Medicaid Services
10. New Jersey Division of Aging Services: Pharmaceutical Assistance to the Aged and Disabled (PAAD) New Jersey Department of Human Services, Division of Aging Services

Please note: We do not offer every plan available in your area. Any information we provide is limited to those plans we do offer in your area. Please contact Medicare.gov or 1-800-MEDICARE to get information on all of your options.Garden State Medicare Solutions is not connected with or endorsed by the United States government or the federal Medicare program. Medicare has neither endorsed nor reviewed this information.